Effects of rosuvastatin on post-thrombotic syndrome following deep vein thrombosis: a randomized clinical trial
DOI:
https://doi.org/10.60988/p.v37i2S.196Keywords:
post-thrombotic syndrome; venous thrombosis; rosuvastatin; rivaroxaban; warfarinAbstract
This study evaluates the effectiveness of rosuvastatin as an adjunct to standard anticoagulant therapy in reducing the incidence of post-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT) treated at the Al-Imamain Al-Kadhimain Medical City between October 2022 and September 2024. A total of 465 patients were randomized into two groups: a control group receiving standard anticoagulants (warfarin or rivaroxaban) and an intervention group receiving the same anticoagulants with the addition of rosuvastatin. Over the subsequent three months, the authors assessed the development of PTS and measured the serum concentrations of D-dimer and C-reactive protein (CRP). The occurrence of PTS was found to be significantly lower in the rosuvastatin group compared to the control group (p=0.021), with no severe adverse events reported. Furthermore, the intervention group exhibited marked reductions in CRP and D-dimer levels, suggesting that rosuvastatin may contribute to improved clinical outcomes in the management of DVT. These findings support the incorporation of rosuvastatin into conventional anticoagulant regimens as a means of mitigating PTS risk and enhancing overall recovery. The study underscores the value of adjunct therapies in reducing long-term complications associated with venous thromboembolism.
References
1. Mohialdeen S., Fayadh N.A.H., Al-Anbari A.J.K., Al-Alosi B.M.H. Acute arterial thrombosis in patients admitted with COVID-19 infection: clinical experience. J. Emerg. Med. Trauma Acute Care 2022(2), 5, 2022. DOI: 10.5339/jemtac.2022.ismc.5
2. Brown C., Tokessy L., Delluc A., Carrier M. Risk of developing post thrombotic syndrome after deep vein thrombosis with different anticoagulant regimens: a systematic review and pooled analysis. Thromb. Res. 240, 109057, 2024. DOI: 10.1016/j.thromres.2024.109057
3. Pishgahi M., Ghane Fard S., Lak Tabriz R., Karimi Toudeshki K., Talebi Z. The effects of 3-month rosuvastatin adjuvant therapy on post thrombotic syndrome following deep vein thrombosis; a randomized clinical trial. Arch. Acad. Emerg. Med. 11(1), e43, 2023. DOI: 10.22037/aaem.v11i1.1972
4. Kones R. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Ther. Adv. Cardiovasc. Dis. 3(4), 309–315, 2009. DOI: 10.1177/1753944709337056
5. Kakkos S.K., Gohel M., Baekgaard N., Bauersachs R., Bellmunt-Montoya S., Black S.A., et al. Editor’s choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur. J. Vasc. Endovasc. Surg. 61(1), 9–82, 2021. DOI: 10.1016/j.ejvs.2020.09.023
6. Mostaza J.M., Escobar C. Rosuvastatin-based lipid-lowering therapy for the control of LDL cholesterol in patients at high vascular risk. J. Clin. Med. 13(7), 1894, 2024. DOI: 10.3390/jcm13071894
7. Ramberg C., Hindberg K., Biedermann J.S., Cannegieter S.C., van der Meer F.J., Snir O., et al. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: a randomized controlled trial. J. Thromb. Haemost. 20(4), 877–887, 2022. DOI: 10.1111/jth.15626
